Heron Therapeutics' stock price surge may be positive, but t...
Heron Therapeutics' stock price surge may be positive, but the company's core business performance will decide the sustainability of this turnaround. Lack of profitability and minimal revenue growth could discourage potential investors.
Investors in Heron Therapeutics (NASDAQ:HRTX) From Five Years Ago Are Still Down 88%, Even After 21% Gain This Past Week
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment